儿童关节炎与风湿病研究联盟多关节型幼年特发性关节炎共识治疗方案研究:三年结局与潜在类别轨迹分析
该研究基于CARRA注册队列中297例多关节型JIA患儿,比较升阶梯治疗(SU,n=190)、早期联合治疗(EC,n=76)和生物制剂首选(n=31)三种方案至三年的结局,并用潜在类别轨迹模型分析疾病轨迹。结果显示EC在临床缓解用药(CRM)、处于临床非活动性疾病(CID)时间比例和cJADAS-10非活动性疾病时间比例上优于SU,基线后两个月内启动bDMARD与快速改善轨迹相关。
要点
- 三年时EC组CRM达59.9%,优于SU组的40.6%(P=0.012)。
- EC组处于CID的时间比例为38%,高于SU组的30%(P=0.04)。
- 基线后第一个月内启动bDMARD的OR为5.33,第二个月为2.67,均与快速改善轨迹相关。
核心结论
- 在三年观察期内,早期联合治疗在反映较低疾病活动度时间比例的结局上优于升阶梯治疗。
- 基线后两个月内启动bDMARD可预测快速改善和维持非活动性疾病。
- 这些结果支持早期启动bDMARD可降低多关节型JIA总体疾病负担的假说。
研究设计与样本
- 基于儿童关节炎与风湿病研究联盟(CARRA)注册队列,纳入有多关节型JIA且随访至三年的参与者。
- 共纳入297例参与者:升阶梯治疗(SU)组190例,早期联合治疗(EC)组76例,生物制剂首选组31例。
- 采用潜在类别轨迹模型(LCTM)识别三年内疾病病程相似的参与者亚组。
主要发现
- 三年随访时,SU组、EC组和生物制剂首选组达到CID的比例分别为35%、42%和44%(SU vs EC,P=0.35)。
- EC组在达到CRM方面优于SU组(59.9% vs 40.6%;P=0.012)。
- EC组处于CID的时间比例为38%,SU组为30%(P=0.04)。
- EC组处于cJADAS-10非活动性疾病的时间比例为51%,SU组为41%(P=0.02)。
- LCTM识别出缓慢、中度和快速改善三种轨迹;基线后第一个月内启动bDMARD的OR为5.33,第二个月启动的OR为2.67,均与快速改善轨迹相关。
关键数值与推荐
- 临床非活动性疾病(CID)定义为无糖皮质激素使用的ACR临床非活动性疾病。
- cJADAS-10非活动性疾病(cJADAS-10-ID)定义为cJADAS-10≤2.5。
- 临床缓解用药(CRM)为研究评估的结局之一。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the impact of differences in the timing of initial biologic disease-modifying antirheumatic drug (bDMARD) therapy using the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Start Time Optimization of biologics in Polyarticular Juvenile Idiopathic Arthritis (JIA) (STOP-JIA) - consensus treatment plans study on outcomes through three years. METHODS: Start Time Optimization of biologics in Polyarticular-JIA participants with CARRA Registry follow-up through three years were eligible. Outcomes included American College of Rheumatology clinically inactive disease (CID) off glucocorticoids, clinical Juvenile Arthritis Disease Activity Score based on 10 joints inactive disease (cJADAS-10-ID) (cJADAS-10-ID: cJADAS-10 ≤ 2.5), clinical remission on medication (CRM), and proportion of time in CID and/or cJADAS-10-ID. Latent class trajectory modeling (LCTM) was applied to identify participant subgroups sharing similar disease courses over this period. RESULTS: A total of 297 participants were included (n = 190 step-up [SU], 76 early combination [EC], and 31 biologic first). At the three-year visit, CID was achieved by 35%, 42%, and 44%, respectively (P = 0.35 for SU versus EC). EC was superior to SU in achieving CRM (59.9% vs 40.6%; P = 0.012), time spent in CID (38% versus 30%; P = 0.04), and cJADAS-10-ID (51% versus 41%; P = 0.02). Slow, moderate, and rapid improvement trajectories were identified by LCTM; bDMARD initiation within the first (odds ratio [OR] 5.33) or second (OR 2.67) month from baseline was associated with the rapid improvement trajectory. CONCLUSION: EC was superior to SU across three years for outcomes reflecting time spent in lower disease activity. Starting bDMARD within two months predicted rapid improvement and maintenance of inactive disease. These results support the hypothesis that early bDMARD initiation reduces overall disease burden in pJIA.
引用
- Ringold S, Ong MS, Tomlinson G, et al. Three-Year Outcomes and Latent Class Trajectory Analysis of the Childhood Arthritis and Rheumatology Research Alliance Polyarticular JIA Consensus Treatment Plans Study. Arthritis Rheumatol. 2025. PMID: 40344490. doi:10.1002/art.43216
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。